UM  > 中華醫藥研究院
Research and development of mAb drugs in China: a look from policy perspectives
Rong Jiang1,2; Yuanyuan Sun1; Carolina Ung3; Xinyue Dong1; Xiangjun Kong2; Yuanjia Hu3; Rong Shao1,2
2019-05
Source PublicationHUMAN VACCINES & IMMUNOTHERAPEUTICS
ISSN2164-5515
Volume15Issue:11Pages:2695-2705
Abstract

Background: Monoclonal antibody (mAb) drugs are increasingly important for the pharmaceutical industry across the globe. In China, mAb drug developments face many challenges. Multiple policies have been implemented recently to reinforce support in various areas. This study aims to investigate the latest landscape of mAb drugs in China from policy perspectives encompassing R&D, clinical trials, marketing approval, and talent pools.

Methods: Information about mAb drugs approved in the United States, the European Union, Japan, and China by 2017 and mAb-related policies in China were retrieved from government websites and third-party statistical databases for descriptive, statistical, and comparative analysis.

Results and discussion: In China, 21 mAb drugs (10 locally-developed and 11 imported) have so far been approved. For the 11 imported mAb drugs in China, the median drug lag in the marketing approval was estimated at 87.1 months, compared with the U.S. (0 months), the EU (8.9 months), and Japan (43.4 months). However, as far as the dramatically changing innovation supporting system in China is concerned, emergence of new biopharmaceutical companies, transformation of the current drug companies and their shift to antibody therapy, and the pooling of high-level talent contribute to mAb development in China. The number of clinical trials and marketing applications and approvals involving mAb drugs is also growing. Favorable policies will continue to play a role in the sustainable development of mAb drugs in China.

Conclusion: The research showed that the reform of multiple policies and incentives for attracting/retaining high-level talent has evidently been effective in addressing the drug lag of mAb drugs in China. In future development, China should actively monitor the global R&D outcomes and industrial development trends of mAb drugs and make the policy environment more attractive to enable more mAb drugs to be marketed in China as soon as possible.

Keywordr&d Support And Guidance Policy Clinical Trial Policy Drug Lag Innovation Support System Mab Drugs Marketing Approval Policy
DOI10.1080/21645515.2019.1605809
Indexed BySCI
Language英语
WOS Research AreaBiotechnology & Applied Microbiology ; Immunology
WOS SubjectBiotechnology & Applied Microbiology ; Immunology
WOS IDWOS:000469611300001
Fulltext Access
Citation statistics
Document TypeJournal article
CollectionInstitute of Chinese Medical Sciences
Corresponding AuthorRong Shao
Affiliation1.School of International Pharmaceutical Business, China Pharmaceutical University, Jiangsu, China
2.The Research Center of National Drug Policy &Ecosystem, Nanjing, China
3.State Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau,Macau, China
Recommended Citation
GB/T 7714
Rong Jiang,Yuanyuan Sun,Carolina Ung,et al. Research and development of mAb drugs in China: a look from policy perspectives[J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS,2019,15(11):2695-2705.
APA Rong Jiang.,Yuanyuan Sun.,Carolina Ung.,Xinyue Dong.,Xiangjun Kong.,...&Rong Shao.(2019).Research and development of mAb drugs in China: a look from policy perspectives.HUMAN VACCINES & IMMUNOTHERAPEUTICS,15(11),2695-2705.
MLA Rong Jiang,et al."Research and development of mAb drugs in China: a look from policy perspectives".HUMAN VACCINES & IMMUNOTHERAPEUTICS 15.11(2019):2695-2705.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Rong Jiang]'s Articles
[Yuanyuan Sun]'s Articles
[Carolina Ung]'s Articles
Baidu academic
Similar articles in Baidu academic
[Rong Jiang]'s Articles
[Yuanyuan Sun]'s Articles
[Carolina Ung]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Rong Jiang]'s Articles
[Yuanyuan Sun]'s Articles
[Carolina Ung]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.